Events8th International Electronic Conference on Medicinal Chemistry
Published
This submission belongs to the session S4. Small molecules as drug candidates of the event 8th International Electronic Conference on Medicinal Chemistry
Published date
01 Nov, 2022
Academic Editor
author-avatarAlfredo Berzal-Herranz
Citation
Syeda Abiha Rizvi, Nousheen Mushtaq, Ahsaan Ahmad, Laila Anwer, Saira Asghar, Mariam Arefa, Anam Zehra, Madiha Arif, Farah Batool, 4’4 bromophenyl 4’piperidinol Derivatives as a Multifactorial anti -Alzheimer agent: Synthesis, In Vitro, and In- Silico based Studies, in Proceedings of 8th International Electronic Conference on Medicinal Chemistry, 1 November–30 November 2022, MDPI: Basel, Switzerland, doi: 10.3390/ECMC2022-13265
Share
Email
Facebook
Twitter
LinkedIn

4’4 bromophenyl 4’piperidinol Derivatives as a Multifactorial anti -Alzheimer agent: Synthesis, In Vitro, and In- Silico based Studies

Laila Anwer 4
Mariam Arefa 1
Anam Zehra 1
Madiha Arif 1
Farah Batool 1
1. Department of Pharmaceutical Chemistry, Faculty of Pharmacy & Pharmaceutical Sciences, University of Karachi; Pakistan
2. 1 Department of Pharmaceutical Chemistry, Faculty of Pharmacy & Pharmaceutical Sciences, University of Karachi; Pakistan
3. 2 Department of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, Jinnah Sindh Medical University, Karachi, Pakistan
4. Department of Pharmacology, Faculty of Pharmacy, Hamdard University, Karachi, Pakistan
5. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Hamdard University, Karachi, Pakistan
Abstract

Abstract: 4’4 bromophenyl 4’piperidinol derivatives were synthesized, and evaluated as multifactorial agents for the treatment of Alzheimer’s disease (AD). Among all the analogues, AB11 and AB14 showed the best activity against acetylcholinesterase (AChE) with IC50 = 0.029 μM and 0.038 μM respectively. Both compounds also acted as a good antioxidant agents (IC50 = 26.38 μM for AB11 and 23.99 μM for AB14) while AB11 is the only molecule that displayed moderate inhibition of amyloid beta (Aβ) (43.25% at 500 μM). AB11 and AB14 were found selective against monoamine oxidase-B (MAO-B) with IC50 values of 866 μM and 763 μM respectively. AB10, AB17, and AB70 exhibited activity against both MAO-A and MAO-B and showed inhibitory potential against acetylcholinesterase, moreover, all analogues are capable of disassembling the well-structured Aβ fibril. Molecular modeling of selected compounds displayed interactions with the active site of human MAO-B and AChE enzyme. The results suggested that AB11 is a promising multi-target hit that can be optimized further as a successful drug molecule for the treatment of AD.

Keywords
4’4 bromophenyl 4’piperidinol
Alzheimer’s disease (AD)
acetylcholinesterase
Molecular modeling
Monoamine oxidase (MAO)
antioxidant
Aβ aggregation and disaggregation.
Poster
sciforum-066017.pdf
Small molecule inhibitors of bacterial quorum sensing
Binding to proteins of the pharmacologically active bis(maltolato)oxidovanadium(IV)